I think this might be an entry point for ESPR. It is down ~20%. They are hit from the SNY/REGN panel yesterday. ESPR -23% on yesterday’s SNY/REGN panel. SNY/REGN—FDA panel backs Praluent with reservations in 13-3 vote: http://www.wsj.com/articles/fda-panel-backs-cholesterol-drug-but-raises-concerns-1433884972 A Food and Drug Administration advisory panel recommended that the agency approve the cholesterol-lowering drug Praluent, the first of a wave of such cardiovascular drugs [PCSK9] expected to raise billions of dollars in revenue and perhaps alter the treatment of cardiovascular disease. But many panelists said the use of the drug should be limited to certain high-risk groups, such as people with very high cholesterol for genetic reasons because of a condition called familial hypercholesterolemia. The committee voted 13-3 in favor of Praluent, from France’s Sanofi and Regeneron Pharmaceuticals Inc. But enough panelists expressed caution about the evidence in the companies’ studies, and so it may take longer than the industry would like to get these medicines widely used. Esperion Therapeutics Inc. (NASDAQ:ESPR) http://www.esperion.com/ https://www.google.com/finance?q=NASDAQ:ESPR ETC-1002 http://www.esperion.com/therapies-progress/etc-1002/ ETC-1002 is a novel, first-in-class, orally available, once-daily LDL-C lowering small molecule designed to lower levels of LDL-C and to avoid side effects associated with existing LDL-C lowering therapies. ETC-1002 has a unique dual mechanism of action that has the potential to regulate both lipid and carbohydrate metabolism. ETC-1002 appears to work by inhibiting ATP citrate lyase (ACL), a key enzyme in the cholesterol biosynthetic pathway, and activating a complementary enzyme, 5′-adenosine monophosphate-activated protein kinase (AMPK). Both enzymes are known to play significant roles in the synthesis of cholesterol and glucose in the liver. By inhibiting cholesterol synthesis in the liver, ETC-1002 causes the liver to take up LDL particles from the blood, which reduces LDL-C levels.